左旋氨氯地平联合依那普利治疗肾性高血压的临床效果观察

Observation on the Clinical Efficacy of Levamlodipine Besylate and Enalapril in the Treatment of Renal Hypertension

目的观察左旋氨氯地平联合依那普利治疗肾性高血压的临床疗效。方法将2010年3月—2013年2月间入选的76例肾性高血压患者按照随机数字表分为观察组(n=41例)与对照组A(n=35例),观察组患者予左旋氨氯地平联合依那普利方案,对照组予硝苯地平联合依那普利方案,疗程8周,疗程结束后对比两组血压与肾功能变化。结果①两组治疗后血压值较治疗前明显下降(P<0.05),观察组患者血压值较之对照组下降更为明显,差异有统计学意义(P<0.05)。②两组患者治疗后Scr、BUN、24h尿蛋白定量均较治疗前下降,其中观察组BUN、24 h尿蛋白定量与治疗前水平,差异有统计学意义(P<0.05),且24 h尿蛋白定量明显低于对照组水平(P<0.05)。结论左旋氨氯地平联合依那普利治疗肾性高血压降压效果明显,且能一定程度上保护肾功能,具有临床推广价值。

Objective To observe the clinical efficacy of levamlodipine besylate and enalapril in the treatment of renal hyperten- sion. Methods 76 admitted renal hypertension patients from March, 2010 to February, 2013 were randomly divided into observa- tion group （n=41cases） and control group （n=35cases）. The observation group was treated with levamlodipine besylate and enalapril scheme, the control group was treated with nifedipine and enalapril scheme, for 8 weeks, a course of treatment. And after the treat- ment, the blood pressure value and renal function were compared between 2 groups. Results ①Blood pressure values of 2 groups were both obviously lower than those pre-treatment （P〈0.05）, the blood pressure values of observation group patients decreased more significantly than those of the control group, the difference was statistically significant（P〈0.05）. ② Set, BUN and 24h urinary protein of 2 groups of patients after treatment decreased than those pre-treatment, BUN and 24 h urinary protein of the observation group had statistically significant difference compared with those pre-treatment （P〈0.05）, and 24 h urine protein were significantly lower than that of the control group（P〈0.05）. Conclusion Levamlodipine besylate and enalapril have good effect on renal hyperten- sion, and can protect renal function to a certain extent, which have the value of clinical promotion.